The Fund seeks investment results that correspond generally to the price and yield of an equity index called the NYSE Arca Biotechnology Index. The Fund normally invests at least 90% of its net assets ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

The latest deals are Sino Biopharmaceutical's partnership with France's Sanofi and Antengene's agreement with Belgium's UCB The pace and size of outlicensing deals between Chinese drug makers and ...